Latest Conference Articles

Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.

Zanubrutinib was associated with improved cost savings and quality-adjusted life year benefits vs acalabrutinib in B-cell malignancies.

Arsenic trioxide plus all-trans retinoic acid & idarubicin improved EFS vs standard ATRA and anthracycline-based chemotherapy in high-risk APL.

Adding fixed-duration glofitamab-gxbm (Columvi) to gemcitabine and oxaliplatin led to a statistically significant and clinically meaningful improvement in survival vs rituximab (Rituxan) plus gemcitabine/oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.

Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.

The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.

Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.

The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.

Ponatinib, chemo, and alloHSCT offer long-term survival in adult Ph+ ALL, per 4-year PONALFIL trial data at 2024 EHA Congress.

Englumafusp alfa plus glofitamab showed activity and tolerability in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.

The CD7-targeted CAR T-cell therapy WU-CART-007 had a manageable safety profile and elicited preliminary efficacy signals in relapsed/refractory T-ALL/LBL.

Blinatumomab consolidation improved MRD clearance over chemotherapy in DS B-ALL patients, according to ALLTogether1 DS study results.

Time from diagnosis, elevated WBC count, and VAF were all significantly associated with an increased risk of disease progression of polycythemia vera.

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.

HOVON-146 showed integrating blinatumomab into pre-phase and consolidation therapy improved outcomes in newly diagnosed B-ALL.

Over a 4-year period, most patients with lower-risk myelofibrosis experienced disease progression, according to the prospective MOST study.

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Zanubrutinib/venetoclax elicited a 100% overall response rate in untreated chronic lymphocytic leukemia harboring 17p deletions or TP53 mutations.

Ide-cel induced improved PFS outcomes in patients with relapsed/refractory multiple myeloma with characteristics including lower tumor burden.

Talquetamab proved safe and effective for relapsed/refractory myeloma, even in patients with comorbidities.

Clinical benefit generated from treatment with lurbinectedin plus irinotecan was noted across sensitive and resistant patient populations with SCLC.

Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.

The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.

A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

MammaPrint high 2 HR-positive/HER2-negative early-stage breast cancer exhibited a heightened immune active state.

Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.